RU2002131886A - Азабициклические карбаматы и их применение в качестве агонистов альфа-7 никотинового ацетилхолинового рецептора - Google Patents
Азабициклические карбаматы и их применение в качестве агонистов альфа-7 никотинового ацетилхолинового рецептора Download PDFInfo
- Publication number
- RU2002131886A RU2002131886A RU2002131886/04A RU2002131886A RU2002131886A RU 2002131886 A RU2002131886 A RU 2002131886A RU 2002131886/04 A RU2002131886/04 A RU 2002131886/04A RU 2002131886 A RU2002131886 A RU 2002131886A RU 2002131886 A RU2002131886 A RU 2002131886A
- Authority
- RU
- Russia
- Prior art keywords
- free base
- acid addition
- addition salt
- compound
- formula
- Prior art date
Links
- POPPVIRYGJQIOF-UHFFFAOYSA-N 2-acetyloxyethyl(trimethyl)azanium;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(=O)OCC[N+](C)(C)C.CN1CCCC1C1=CC=CN=C1 POPPVIRYGJQIOF-UHFFFAOYSA-N 0.000 title 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 title 1
- 108010009685 Cholinergic Receptors Proteins 0.000 title 1
- 102000034337 acetylcholine receptors Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 14
- 239000002253 acid Substances 0.000 claims 12
- 239000012458 free base Substances 0.000 claims 12
- 208000028017 Psychotic disease Diseases 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- -1 1- (2-fluorophenyl) ethyl Chemical group 0.000 claims 3
- FZCCWBIUMZOAMX-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-ylcarbamic acid Chemical compound C1CC2C(NC(=O)O)CN1CC2 FZCCWBIUMZOAMX-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0010955.3 | 2000-05-05 | ||
| GBGB0010955.3A GB0010955D0 (en) | 2000-05-05 | 2000-05-05 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002131886A true RU2002131886A (ru) | 2004-04-10 |
Family
ID=9891092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002131886/04A RU2002131886A (ru) | 2000-05-05 | 2001-05-03 | Азабициклические карбаматы и их применение в качестве агонистов альфа-7 никотинового ацетилхолинового рецептора |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6780861B2 (enExample) |
| EP (1) | EP1282620B1 (enExample) |
| JP (1) | JP4898062B2 (enExample) |
| KR (1) | KR20020093974A (enExample) |
| CN (1) | CN1167703C (enExample) |
| AR (1) | AR028073A1 (enExample) |
| AT (1) | ATE263167T1 (enExample) |
| AU (2) | AU2001262257B2 (enExample) |
| BR (1) | BR0110521A (enExample) |
| CA (1) | CA2407972C (enExample) |
| CZ (1) | CZ20023622A3 (enExample) |
| DE (1) | DE60102581T2 (enExample) |
| DK (1) | DK1282620T3 (enExample) |
| ES (1) | ES2218418T3 (enExample) |
| GB (1) | GB0010955D0 (enExample) |
| HK (1) | HK1054223B (enExample) |
| HU (1) | HUP0301866A2 (enExample) |
| IL (1) | IL152417A0 (enExample) |
| MX (1) | MXPA02010892A (enExample) |
| NO (1) | NO20025280D0 (enExample) |
| NZ (1) | NZ522226A (enExample) |
| PE (1) | PE20020221A1 (enExample) |
| PL (1) | PL357435A1 (enExample) |
| PT (1) | PT1282620E (enExample) |
| RU (1) | RU2002131886A (enExample) |
| SK (1) | SK15612002A3 (enExample) |
| TR (1) | TR200401007T4 (enExample) |
| WO (1) | WO2001085727A1 (enExample) |
| ZA (1) | ZA200208969B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6262265A (ja) * | 1985-09-13 | 1987-03-18 | Hitachi Ltd | 復水器自動検査補修システム |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| PE20021019A1 (es) * | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| BR0213501A (pt) * | 2001-11-02 | 2004-08-24 | Searle Llc | Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US6852716B2 (en) * | 2002-02-15 | 2005-02-08 | Pfizer Inc | Substituted-aryl compounds for treatment of disease |
| CA2476624A1 (en) * | 2002-02-19 | 2003-08-28 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
| DE10234424A1 (de) * | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| CA2499128C (en) * | 2002-09-25 | 2012-07-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| ATE378048T1 (de) | 2002-12-06 | 2007-11-15 | The Feinstein Inst Medical Res | Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten |
| US7238715B2 (en) | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| JP2006521345A (ja) * | 2003-03-28 | 2006-09-21 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ニコチン性アセチルコリン受容体の正のアロステリック調節剤 |
| PL1697378T3 (pl) * | 2003-12-22 | 2008-04-30 | Memory Pharm Corp | Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania |
| US20050170360A1 (en) * | 2004-01-30 | 2005-08-04 | Papke Roger L. | Variant neuronal nicotinic alpha-7 receptor and methods of use |
| ATE437880T1 (de) * | 2004-02-04 | 2009-08-15 | Neurosearch As | Dimere azacyclische verbindungen und deren verwendung |
| WO2005092890A2 (en) | 2004-03-25 | 2005-10-06 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| DE602005024677D1 (de) * | 2004-04-22 | 2010-12-23 | Memory Pharm Corp | Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen |
| RU2386633C2 (ru) * | 2004-05-07 | 2010-04-20 | Мемори Фармасьютиклз Корпорейшн | 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| JP2008525464A (ja) * | 2004-12-22 | 2008-07-17 | メモリー・ファーマシューティカルズ・コーポレイション | α−７ニコチン性受容体リガンド並びにその製造及び使用 |
| US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| GB0525673D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| HUE026815T2 (en) | 2008-11-19 | 2016-07-28 | Forum Pharmaceuticals Inc | Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| AU2010247835A1 (en) * | 2009-05-11 | 2011-12-08 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors |
| EP2456438A2 (en) * | 2009-07-23 | 2012-05-30 | Novartis AG | Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives |
| TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
| JP5633405B2 (ja) * | 2010-02-18 | 2014-12-03 | Jsr株式会社 | 新規化合物、感放射線性組成物及び硬化膜 |
| CN102823159A (zh) * | 2010-03-26 | 2012-12-12 | 康宁股份有限公司 | 低非线性长距离光传输系统 |
| TWI519532B (zh) | 2010-05-17 | 2016-02-01 | 艾維沃製藥公司 | （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體 |
| CA2808797A1 (en) | 2010-07-26 | 2012-02-02 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors |
| US20140171448A1 (en) * | 2011-01-27 | 2014-06-19 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
| EA201391348A8 (ru) * | 2011-03-18 | 2014-11-28 | Новартис Аг | КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА |
| LT2685986T (lt) * | 2011-03-18 | 2020-03-10 | Genzyme Corporation | Gliukozilceramido sintazės slopiklis |
| RU2611627C2 (ru) * | 2011-04-29 | 2017-02-28 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Алкалоидный эфир и карбаматные производные и их медицинские композиции |
| IN2014CN03647A (enExample) * | 2011-10-20 | 2015-10-09 | Novartis Ag | |
| RU2017136693A (ru) | 2012-05-08 | 2019-02-08 | Форум Фармасьютикалз, Инк. | Способы поддержания, лечения или улучшения когнитивной функции |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| BR112015013771B1 (pt) | 2012-12-11 | 2022-10-04 | Novartis Ag | Composição que compreende um ativador do receptor alfa 7, nicotínico de acetilcolina (nachr) como biomarcador preditivo de resposta ao tratamento de ativador do dito receptor |
| US20150313884A1 (en) | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| MX379289B (es) * | 2013-01-15 | 2025-03-10 | Novartis Ag | Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. |
| JP6137336B2 (ja) * | 2013-01-15 | 2017-05-31 | ノバルティス アーゲー | ナルコレプシーの処置のためのアルファ７ニコチン性受容体アゴニストの使用 |
| EP2945633B1 (en) | 2013-01-15 | 2021-06-30 | Novartis AG | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| PT3920912T (pt) | 2019-02-04 | 2025-09-09 | Genzyme Corp | Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs) |
| IL295255A (en) | 2020-02-03 | 2022-10-01 | Genzyme Corp | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| IL300090A (en) | 2020-07-24 | 2023-03-01 | Genzyme Corp | Pharmaceutical preparations containing VENGLUSTAT |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical compositions containing them |
| AU7545894A (en) * | 1993-09-02 | 1995-03-22 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| ZA957746B (en) * | 1994-09-14 | 1996-07-25 | Lundbeck & Co As H | Carbamoyloxy amine compounds |
| GB9525261D0 (en) | 1995-12-11 | 1996-02-07 | Bayer Ag | Carbamic acid derivatives |
| GB9526560D0 (en) * | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| DE69727679T2 (de) * | 1996-06-05 | 2004-07-22 | Lindner, Wolfgang, Prof. Dr. | Auf cinchonan basierte chirale selektoren zur trennung von stereoisomeren |
| US6525065B1 (en) * | 1997-06-30 | 2003-02-25 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| US6624173B1 (en) * | 1997-06-30 | 2003-09-23 | Targacept, Inc. | Pharmaceutical compositions for treating and/or preventing CNS disorders |
| US5988429A (en) * | 1997-10-14 | 1999-11-23 | Pharmadesign, Inc. | Blister pack pill dispenser |
| HUP0203514A3 (en) * | 1999-09-28 | 2004-01-28 | Eisai Co Ltd | Quinuclidine compounds and drugs containing them and process for preparation the same |
| AU2001282874A1 (en) * | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| GB0109871D0 (en) * | 2001-04-20 | 2001-06-13 | Glaxo Group Ltd | Metering method for particulate material |
-
2000
- 2000-05-05 GB GBGB0010955.3A patent/GB0010955D0/en not_active Ceased
-
2001
- 2001-05-03 WO PCT/EP2001/005008 patent/WO2001085727A1/en not_active Ceased
- 2001-05-03 DK DK01936319T patent/DK1282620T3/da active
- 2001-05-03 MX MXPA02010892A patent/MXPA02010892A/es unknown
- 2001-05-03 PE PE2001000399A patent/PE20020221A1/es not_active Application Discontinuation
- 2001-05-03 KR KR1020027014760A patent/KR20020093974A/ko not_active Withdrawn
- 2001-05-03 AR ARP010102089A patent/AR028073A1/es not_active Application Discontinuation
- 2001-05-03 RU RU2002131886/04A patent/RU2002131886A/ru not_active Application Discontinuation
- 2001-05-03 PL PL01357435A patent/PL357435A1/xx not_active Application Discontinuation
- 2001-05-03 HU HU0301866A patent/HUP0301866A2/hu unknown
- 2001-05-03 HK HK03104830.3A patent/HK1054223B/en not_active IP Right Cessation
- 2001-05-03 JP JP2001582328A patent/JP4898062B2/ja not_active Expired - Fee Related
- 2001-05-03 EP EP01936319A patent/EP1282620B1/en not_active Expired - Lifetime
- 2001-05-03 AU AU2001262257A patent/AU2001262257B2/en not_active Ceased
- 2001-05-03 NZ NZ522226A patent/NZ522226A/en unknown
- 2001-05-03 AT AT01936319T patent/ATE263167T1/de active
- 2001-05-03 TR TR2004/01007T patent/TR200401007T4/xx unknown
- 2001-05-03 US US10/258,920 patent/US6780861B2/en not_active Expired - Fee Related
- 2001-05-03 SK SK1561-2002A patent/SK15612002A3/sk unknown
- 2001-05-03 AU AU6225701A patent/AU6225701A/xx active Pending
- 2001-05-03 CZ CZ20023622A patent/CZ20023622A3/cs unknown
- 2001-05-03 ES ES01936319T patent/ES2218418T3/es not_active Expired - Lifetime
- 2001-05-03 PT PT01936319T patent/PT1282620E/pt unknown
- 2001-05-03 CA CA002407972A patent/CA2407972C/en not_active Expired - Fee Related
- 2001-05-03 IL IL15241701A patent/IL152417A0/xx unknown
- 2001-05-03 CN CNB01808821XA patent/CN1167703C/zh not_active Expired - Fee Related
- 2001-05-03 BR BR0110521-3A patent/BR0110521A/pt not_active Application Discontinuation
- 2001-05-03 DE DE60102581T patent/DE60102581T2/de not_active Expired - Lifetime
-
2002
- 2002-11-04 NO NO20025280A patent/NO20025280D0/no not_active Application Discontinuation
- 2002-11-05 ZA ZA200208969A patent/ZA200208969B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2407972A1 (en) | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | |
| CA3106490C (en) | [1,2,4]triazolo[1,5-a]pyridine compound as jak inhibitor and use thereof | |
| JP2003532731A5 (enExample) | ||
| RU98102128A (ru) | Производные бензо[g]хинолина | |
| CA2284732A1 (en) | Analogs of cocaine | |
| TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
| PE20020721A1 (es) | Derivados de quinuclidina como agentes antimuscarinicos m3 | |
| NZ587547A (en) | Modulators of ATP-Binding Cassette Transporters | |
| KR0139626B1 (ko) | 강심제 | |
| CA2284977A1 (en) | 3,3-disubstituted propylamines, their use and preparation | |
| RU95113148A (ru) | Производное 2-(2-амино-1,6-дигидро-6-оксопурин-9-ил)-метокси-1,3-пропандиола | |
| RU2001133004A (ru) | Применение селективных антагонистов альфа1b-адренергического рецептора для улучшения состояния при сексуальной дисфункции | |
| ES8801245A1 (es) | Un procedimiento para preparar derivados de piperidina | |
| KR20150020301A (ko) | 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물 | |
| RU2005101876A (ru) | Производные аминоспиртов | |
| RU95110937A (ru) | Хинолоновые и акридиноновые соединения, способ их получения, фармацевтическая композиция и промежуточные соединения | |
| KR880007538A (ko) | 피리다조 디아제핀 유도체 | |
| RU2003134629A (ru) | Соединения цефема | |
| CA2315235A1 (en) | Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same | |
| BRPI0620251A2 (pt) | compostos de nitroimidazol | |
| RU2000106042A (ru) | Способ повышения биологической доступности фексофенадина и его производных | |
| US20020151565A1 (en) | Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders | |
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
| RU2004107847A (ru) | Изоксазолпиридиноны и их применение в лечении болезни паркинсона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20050525 |